The effect of fenelidone (Keshenda) in reducing proteinuria and clinical feedback from patients

Finerenone (Finerenone) is a new type of non-steroidal selective mineral corticoid receptor antagonist, mainly used for the treatment of patients with chronic kidney disease and type 2 diabetes. Clinical studies have shown that fenelinone can reduce glomerular inflammation and fibrosis by inhibiting excessive activation of mineralocorticoid receptors, thereby significantly reducing proteinuria and playing a positive role in protecting renal function. Compared with traditional ACE inhibitors or ARBs, fenelidone has shown good synergistic effects in the control of proteinuria.

In actual clinical application, multiple clinical trials such as FIDELIO-DKD and FIGARO-DKD have shown that fenelidone can significantly reduce urinary albumin/creatinine ratio (UACR). Research results show that after 6 months to 1 years of treatment, patients’ proteinuria levels dropped by an average of 20%to 30%, and some patients even exceed 50%, suggesting that fenelidone has a stable and long-lasting effect in reducing proteinuria. This improvement in proteinuria not only helps delay further decline in kidney function but also reduces the risk of cardiovascular events.

Judging from patient clinical feedback, after using fenelinone, most patients can observe a decrease in urinary protein amount and remain relatively stable during follow-up. At the same time, patients generally report that the drug is well tolerated and the incidence of adverse reactions is low, mainly including mild hyperkalemia and occasional minor headaches or fatigue. By regularly reviewing serum potassium and renal function indicators, most patients can safely continue treatment, indicating that fenelidone can effectively control proteinuria and has manageable safety in actual clinical practice.

In addition, patients usually cooperate with lifestyle management during medication, such as low-salt diet, blood sugar and blood pressure control, which helps to further enhance the anti-proteinuric effect of fenelidone. Clinicians will also adjust the dosage or use a combination of ACEI/ARB according to the patient's specific conditions to achieve individualized treatment goals. Overall, fenelidone has achieved positive clinical feedback in reducing proteinuria, providing an effective and safe treatment option for patients with chronic kidney disease and type 2 diabetes.

Reference materials:https://www.drugs.com/